文献速递骨质疏松与代谢性骨病创伤骨科

德国2型糖尿病患者使用二肽基肽酶-4抑制剂与骨折风险:真实世界数据的回顾性分析

Use of dipeptidyl peptidase-4 inhibitors and risk of bone fracture in patients with type 2 diabetes in Germany-A retrospective analysis of real-world data.
PubMed 文献 · Osteoporos Int · 2017-04-29

在德国初级保健机构治疗的2型糖尿病患者中,使用二肽基肽酶-4抑制剂(DPP4i)联合二甲双胍与二甲双胍单药治疗相比,骨折风险显著降低。研究匹配了4160对DPP4i使用者与从未使用者,5年内骨折发生率分别为6.4%与8.3%,风险比HR=0.67(95%CI 0.54-0.84)。

要点

  • DPP4i联合二甲双胍与二甲双胍单药相比,5年内骨折风险显著降低(HR=0.67)。
  • 女性使用者HR=0.72,男性使用者HR=0.62,骨折风险均显著降低。
  • 5年内骨折发生率:DPP4i使用者6.4% vs 非使用者8.3%。

核心结论

  • DPP4i的使用与骨折风险降低相关。

研究设计与样本

  • 回顾性分析2008年至2014年间来自1262家德国全科医生诊所的首次接受二甲双胍处方的2型糖尿病患者。
  • 按年龄、性别、糖尿病病程、体重指数、索引年份和医生类型1:1匹配4160名DPP4i曾使用者与从未使用者。
  • 主要结局为二甲双胍或DPP4i治疗开始后5年内的骨折发生率,采用时间依赖性Cox回归模型估计风险比(HR)。

主要发现

  • 患者平均年龄61.6岁(SD=11.1岁),59.6%为男性,3.1%在糖尿病专科诊所随访。
  • 平均糖尿病病程1.5年(SD=2.4年),DPP4i使用者HbA1c为7.1%,非使用者为6.6%,体重指数31.5 kg/m2(SD=5.0 kg/m2)。
  • 索引日期后5年内,6.4%的使用者和8.3%的非使用者发生骨折(log-rank p值<0.001)。
  • 5年内女性使用者7.4%、男性使用者4.7%发生骨折,女性非使用者13.3%、男性非使用者8.8%发生骨折(两项log-rank p值均<0.001)。
  • DPP4i使用与骨折风险显著降低相关:所有患者HR=0.67(95%CI 0.54-0.84);女性HR=0.72(95%CI 0.54-0.97);男性HR=0.62(95%CI 0.44-0.88)。

关键数值与推荐

  • DPP4i使用与骨折风险降低相关:所有患者HR=0.67(95%CI 0.54-0.84)。
  • 女性DPP4i使用者HR=0.72(95%CI 0.54-0.97)。
  • 男性DPP4i使用者HR=0.62(95%CI 0.44-0.88)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: In type 2 diabetes patients treated in German primary care practices, the use of dipeptidyl peptidase-4 inhibitor (DPP4i) in combination with metformin was associated with a significant decrease in the risk of developing bone fractures compared to metformin monotherapy. INTRODUCTION: The goal of this study was to analyze the impact of dipeptidyl peptidase-4 inhibitor (DPP4i) use on the risk of bone fracture in patients diagnosed with type 2 diabetes mellitus (T2DM) in Germany. METHODS: Patients with an initial prescription of metformin between 2008 and 2014 from 1262 German general practitioner practices were selected. We matched 4160 DPP4i ever users to never users (1:1) based on age, sex, diabetes duration, body mass index, index year, and physician type. The primary outcome measure was the rate of bone fractures within five years of the start of metformin or DPP-4i therapy. Time-dependent Cox regression models were used to estimate hazard ratios (HRs) for fractures as a function of the DPP4i therapy. RESULTS: The mean age among the patients was 61.6 years (SD = 11.1 years), 59.6% were men, and 3.1% were followed in diabetologist practices. The mean diabetes duration was 1.5 years (SD = 2.4 years), HbA1c levels were 7.1% in DPP4i users and 6.6% in non-users, and body mass index was 31.5 kg/m2 (SD = 5.0 kg/m2). Within five years of the index date, 6.4% of users and 8.3% of non-users developed bone fractures (log-rank p-value < 0.001). Within five years of the index date, 7.4% of female and 4.7% of male users and 13.3% of female and 8.8% of male non-users were diagnosed with bone fractures (both log-rank p-values < 0.001). The use of DPP4i was associated with a significant decrease in the risk of developing bone fractures (all patients HR = 0.67, 95% CI 0.54-0.84; women HR = 0.72, 95% CI 0.54-0.97; men HR = 0.62, 95% CI 0.44-0.88). CONCLUSION: DPP4i use was associated with a decrease in the risk of bone fracture.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Dombrowski S, Kostev K, Jacob L, et al. Use of dipeptidyl peptidase-4 inhibitors and risk of bone fracture in patients with type 2 diabetes in Germany-A retrospective analysis of real-world data. Osteoporos Int. 2017. PMID: 28455750. doi:10.1007/s00198-017-4051-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。